NCT04579679: Open-Label Surufatinib in European Patients With NET

Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: Neuroendocrine tumor (NET)
Recruitment Status: Recruiting
Phase 2
Drug Category: Tyrosine-Kinase Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patients must have progressed on at least 1 prior line of therapy, but no more than 3 therapies
Exclusions: Patients with prior VEGF/VEGFR-targeted therapy; Patients with untreated unstable brain metastases that require treatment- see trial for details

Comments are closed.

Up ↑